WO2000012741A3 - Systeme d'expression inductible - Google Patents

Systeme d'expression inductible Download PDF

Info

Publication number
WO2000012741A3
WO2000012741A3 PCT/FR1999/002051 FR9902051W WO0012741A3 WO 2000012741 A3 WO2000012741 A3 WO 2000012741A3 FR 9902051 W FR9902051 W FR 9902051W WO 0012741 A3 WO0012741 A3 WO 0012741A3
Authority
WO
WIPO (PCT)
Prior art keywords
transcriptional activator
expression system
concerns
inducible
trans
Prior art date
Application number
PCT/FR1999/002051
Other languages
English (en)
Other versions
WO2000012741A2 (fr
WO2000012741A9 (fr
Inventor
Majid Mehtali
Tania Sorg-Guss
Original Assignee
Transgene Sa
Majid Mehtali
Sorg Guss Tania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Majid Mehtali, Sorg Guss Tania filed Critical Transgene Sa
Priority to JP2000567726A priority Critical patent/JP2002523106A/ja
Priority to AU54262/99A priority patent/AU5426299A/en
Priority to CA002341775A priority patent/CA2341775A1/fr
Priority to EP99940240A priority patent/EP1108051A2/fr
Publication of WO2000012741A2 publication Critical patent/WO2000012741A2/fr
Publication of WO2000012741A3 publication Critical patent/WO2000012741A3/fr
Publication of WO2000012741A9 publication Critical patent/WO2000012741A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un système d'expression inductible mettant en oeuvre les séquences nucléotidiques codant pour un activateur transcriptionnel d'origine eucaryote ou virale et un vecteur adénoviral recombinant comportant un gène d'intérêt placé sous le contrôle d'un promoteur inductible en trans par ledit activateur transcriptionnel. Elle a également pour objet un vecteur adénoviral recombinant portant une première cassette d'expression codant pour un activateur transcriptionnel et une seconde cassette portant un gène d'intérêt placé sous le contrôle d'un promoteur inductible en trans par ledit activateur transcriptionnel. L'invention a également trait à une particule virale infectieuse, son procédé de préparation, une cellule eucaryote et une composition pharmaceutique comprenant un tel vecteur ou système d'expression ainsi que leur utilisation à des fins thérapeutiques ou prophylactiques.
PCT/FR1999/002051 1998-08-28 1999-08-27 Systeme d'expression inductible WO2000012741A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000567726A JP2002523106A (ja) 1998-08-28 1999-08-27 誘導的発現系
AU54262/99A AU5426299A (en) 1998-08-28 1999-08-27 Inducible expression system
CA002341775A CA2341775A1 (fr) 1998-08-28 1999-08-27 Systeme d'expression inductible
EP99940240A EP1108051A2 (fr) 1998-08-28 1999-08-27 Systeme d'expression inductible

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810842A FR2782732A1 (fr) 1998-08-28 1998-08-28 Systeme d'expression inductible
FR98/10842 1998-08-28

Publications (3)

Publication Number Publication Date
WO2000012741A2 WO2000012741A2 (fr) 2000-03-09
WO2000012741A3 true WO2000012741A3 (fr) 2000-05-04
WO2000012741A9 WO2000012741A9 (fr) 2001-03-29

Family

ID=9529972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/002051 WO2000012741A2 (fr) 1998-08-28 1999-08-27 Systeme d'expression inductible

Country Status (6)

Country Link
EP (1) EP1108051A2 (fr)
JP (1) JP2002523106A (fr)
AU (1) AU5426299A (fr)
CA (1) CA2341775A1 (fr)
FR (1) FR2782732A1 (fr)
WO (1) WO2000012741A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
NZ521199A (en) * 2000-03-13 2004-11-26 Engene Inc Mucosal cells producing nutrient-regulated protein expressed by a transgene comprising an expression control element linked with a nucleic acid encoding protein, for treating diabetes
AU2003216407A1 (en) * 2002-02-25 2003-09-09 University Of Rochester Dna construct for inducible expression of angiogenic protein and use thereof
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
JP4817657B2 (ja) * 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
CA2502312A1 (fr) * 2002-10-14 2004-04-29 F. Hoffmann-La Roche Ag Cellule transplantable
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2008020318A2 (fr) 2006-03-30 2008-02-21 Engene, Inc. Compositions non virales et procédés de transfection de cellules intestinales in vivo
WO2014066443A1 (fr) 2012-10-23 2014-05-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
WO2016081927A2 (fr) * 2014-11-21 2016-05-26 University Of Florida Research Foundation, Inc. Vecteurs viraux adéno-associés recombinés au génome modifié

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316717A1 (fr) * 1987-11-09 1989-05-24 Daiichi Pharmaceutical Co., Ltd. Procédé de préparation de produits de gènes étrangers
WO1996030512A1 (fr) * 1995-03-31 1996-10-03 Rhone-Poulenc Rorer S.A. Systeme d'expression conditionnel
WO1997031108A1 (fr) * 1996-02-20 1997-08-28 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Recepteur nucleaire de glucocorticoides modifie, proteine de fusion, fragments d'adn codant pour ledit recepteur et ladite proteine de fusion
WO1997038117A1 (fr) * 1996-04-05 1997-10-16 The Salk Institute For Biological Studies Techniques liees a une utilisation d'hormones visant a moduler l'expression de genes exogenes chez des mammiferes et produits connexes
WO1997044475A1 (fr) * 1996-05-20 1997-11-27 Transgene S.A. Vecteurs adenoviraux pour la therapie genique
WO1998037185A2 (fr) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vecteurs pour expression genique regulee

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316717A1 (fr) * 1987-11-09 1989-05-24 Daiichi Pharmaceutical Co., Ltd. Procédé de préparation de produits de gènes étrangers
WO1996030512A1 (fr) * 1995-03-31 1996-10-03 Rhone-Poulenc Rorer S.A. Systeme d'expression conditionnel
WO1997031108A1 (fr) * 1996-02-20 1997-08-28 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Recepteur nucleaire de glucocorticoides modifie, proteine de fusion, fragments d'adn codant pour ledit recepteur et ladite proteine de fusion
WO1997038117A1 (fr) * 1996-04-05 1997-10-16 The Salk Institute For Biological Studies Techniques liees a une utilisation d'hormones visant a moduler l'expression de genes exogenes chez des mammiferes et produits connexes
WO1997044475A1 (fr) * 1996-05-20 1997-11-27 Transgene S.A. Vecteurs adenoviraux pour la therapie genique
WO1998037185A2 (fr) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vecteurs pour expression genique regulee

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRASELMANN S ET AL: "A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 90, no. 5, 1 March 1993 (1993-03-01), pages 1657 - 1661, XP002104567 *
DANIELIAN P ET AL: "Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen.", MOL. ENDOCRINOL., vol. 7, no. 2, February 1993 (1993-02-01), pages 232 - 240, XP002104568 *
FUKUNAGA B ET AL: "Identification of Functional Domains of the Aryl Hydrocarbon Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, no. 48, 8 December 1995 (1995-12-08), pages 29270 - 29278, XP002129578 *
NARUMI K ET AL: "Intermittent, repetitive corticosteroid-induced upregulation of platelet levels after adenovirus-mediated transfer to the liver of a chimeric glucocorticoid-responsive promoter controlling the thrombopoietin cDNA", BLOOD, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 822 - 833, XP002104566 *
OLIGINO T ET AL: "Drug inducible transgene expression in brain using a herpes simplex virus vector", GENE THERAPY, vol. 5, no. 4, April 1998 (1998-04-01), pages 491-496, XP002104570 *
SHIH W ET AL: "AN ADENOVIRAL VECTOR SYSTEM FOR FUNCTIONAL IDENTIFICATION OF NUCLEAR RECEPTOR LIGANDS", MOLECULAR ENDOCRINOLOGY, vol. 5, no. 2, 1 February 1991 (1991-02-01), pages 300 - 309, XP000386396 *
WILSON J: "A pharmacologic rheostat for gene therapy", NAT MED, vol. 2, no. 9, September 1996 (1996-09-01), pages 977 - 978, XP002129577 *

Also Published As

Publication number Publication date
EP1108051A2 (fr) 2001-06-20
CA2341775A1 (fr) 2000-03-09
WO2000012741A2 (fr) 2000-03-09
WO2000012741A9 (fr) 2001-03-29
JP2002523106A (ja) 2002-07-30
FR2782732A1 (fr) 2000-03-03
AU5426299A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
MX9709549A (es) Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
AU2800797A (en) Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1999018226A3 (fr) Vecteurs a base d'alphavirus recombinants a inhibition reduite de synthese macromoleculaire cellulaire
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
WO2001047952A3 (fr) Proteines insecticides provenant de bacillus thuringiensis
BG102612A (en) Complementary adenoviral vector systems and cellular lines
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
ATE213022T1 (de) Adenovirale vektoren für die gentherapie
WO1998056927A3 (fr) Acides nucleiques codant des polypeptides a fonction protease
WO2000012741A3 (fr) Systeme d'expression inductible
DK1222298T3 (da) Vektorer og fremgangsmåder til rekombinant proteinekspression
WO2003060143A3 (fr) Systeme d'expression de proteine efficace
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
WO1999021976A3 (fr) Generation rapide de lignees cellulaires mammiferes stables produisant des niveaux eleves de proteines recombinantes
WO2001025438A3 (fr) Homologues d'interferons alpha
AU6724794A (en) GRB3-3 gene, its variants and their uses
CA2404046A1 (fr) Procedes ameliores et cellules servant a exprimer des produits de proteine de recombinaison
AU4835696A (en) Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells, therapeutic and vaccine applications.
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
WO2001021823A3 (fr) Vecteurs adenoviraux
Callahan Liberal policy's weak foundations.
FI951633A0 (fi) Erittyvien proteiinien lisääntynyt tuotanto eukaryoottisilla yhdistelmäsoluilla
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
AU6833398A (en) Process for the inactivation of genes which code for enzymes for the catabolism of phenyl acetate, plasmids involved in such process and strains transformed t herewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2341775

Country of ref document: CA

Ref country code: CA

Ref document number: 2341775

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 54262/99

Country of ref document: AU

Ref document number: 09763839

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 567726

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999940240

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 13/13, DRAWINGS, PUBLISHED TWICE, REPLACED BY A CORRECT PAGE 12/13

WWP Wipo information: published in national office

Ref document number: 1999940240

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999940240

Country of ref document: EP